How effective is Tysabri for Multiple Sclerosis? (a real world drug study)
Summary:
Overall ratings: 3.5/5 Long term ratings: 3.8/5
This is a phase IV clinical study of how effective Tysabri (natalizumab) is for Multiple sclerosis and for what kind of people. The study is created by eHealthMe from 225 Tysabri users and is updated continuously.
What is Tysabri?
Tysabri has active ingredients of natalizumab. It is often used in multiple sclerosis. eHealthMe is studying from 221,369 Tysabri users. Check the latest studies of Tysabri.
What is Multiple sclerosis?
Multiple sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath) is found to be associated with 1,088 drugs and 1,358 conditions by eHealthMe. Check the latest studies of Multiple sclerosis.
225 people are studied for taking Tysabri in Multiple sclerosis
Overall effectiveness (number of people):
Long term (1+ years) effectiveness (number of people):
Tysabri effectiveness for Multiple sclerosis (number of people):
Overall:
- not at all: 10
- somewhat: 42
- moderate: 45
- high: 85
- very high: 43
Long Term:
- not at all: 2
- somewhat: 20
- moderate: 24
- high: 59
- very high: 37
Gender of people who take Tysabri for Multiple sclerosis *:
- female: 84 %
- male: 16 %
Age of people who take Tysabri for Multiple sclerosis *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 1.33 %
- 20-29: 14.22 %
- 30-39: 24.44 %
- 40-49: 28.44 %
- 50-59: 24.89 %
- 60+: 6.67 %
Who find Tysabri more effective for Multiple Sclerosis?
Gender of people who take Tysabri for Multiple sclerosis *:
- female: 86.72 %
- male: 13.28 %
Age of people who take Tysabri for Multiple sclerosis *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 1.56 %
- 20-29: 17.19 %
- 30-39: 25.0 %
- 40-49: 30.47 %
- 50-59: 20.31 %
- 60+: 5.47 %
* Approximation only. Some reports may have incomplete information.
Do you take Tysabri?
- You can start a phase IV clinical trial to monitor Tysabri safety and effectiveness.How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Related publications that referenced our studies:
- Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
- Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .
- Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
- Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .
Related studies
Alternative drugs to, pros and cons of:
- Tysabri (221,369 reports)
Treatments, associated drugs and conditions:
- Multiple sclerosis (799,636 reports)
How the study uses the data?
The study is based on natalizumab (the active ingredients of Tysabri) and Tysabri (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study neither.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Flolan and Pruritus for Women aged 50-59 - now
- Flolan and Itching for Women aged 50-59 - now
- Prednisolone and Wound for Women aged 60+ - a second ago
- Could Amnesteem cause Dizziness Aggravated? - a second ago
- Coumadin and Nonspecific Back Pain for Women aged 60+ - 8 seconds ago
- Coumadin and Pain - Back for Women aged 60+ - 8 seconds ago
- Coumadin and Back Pain - Nonspecific for Women aged 60+ - 8 seconds ago
- Coumadin and Back Pain for Women aged 60+ - 8 seconds ago
- Gabapentin vs. Prosom, side effect and effectiveness comparison - 11 seconds ago
- Cardiac Failure Chronic and Kidney Infection (Pyelonephritis) - 18 seconds ago